-
2016/2/17
1
(TST) (IGRA)
FDAQuantiFERONTBGoldInTubetest(QFTGIT)TSPOT.TBtest(TSpot)
Risk of TB infection and diseaseamong exposed individuals
Exposure(close contact)
No infection 70% Early progression
(recent TB
-
2016/2/17
2
OT(oldtuberculin)
OTPPD(Mantoux skintesting)
Oldtuberculin(OT) 1908:
Purifiedproteinderivative(PPD) 1939:(FlorenceSiebert)OT
PPDS (SiebertsLot49608) :1TU,5TU,250TU
OT(oldtuberculin)PPD(purifiedproteinderivative)
PPD S PPDSPPDRT23PPDRT232TUPPDS5TU201191PPDRT231TU 2TU
0 1 cc
(Mantoux test)
0.1cc8mm
PPD0.04gmcg2TU
100
4872
-
2016/2/17
3
PPD: PPD:
PPD: : I
>5(mm) X
: II
>10(mm) ,
: III
>15(mm)
-
2016/2/17
4
(Boosting)
13
(+),( ), (),13 (+), (),
:/
PPD
(
-
2016/2/17
5
(IGRAs) QuantiferonTBGoldInTubeAssay
ESAT6,CFP 10,TB7.7 ELISA
Tspot.TB Assay ESAT6,CFP 10
QuantiFERONTBGold
(ESAT6,CFP10)
ESAT6CFP10
QFTTspot.TB assay
83232
-
2016/2/17
6
TspotTB QuantiFERONTBGold
ESAT6/CFP10
ESAT6CFP10
216,, =98%(213/216 =QFT)
Mori,etal.AJRCCM2004;170:5964 532 532
=99.8%(531/532 = QFT) CDC;publicationinpreparation
99,, =96%(95/99=QFT)
Kang,etal.JAMA2005;293:27562761
118,85%,15%
-
2016/2/17
7
QFTTST,
60
70
80
90
100
60
71
7881
Percentpositive
0
10
20
30
40
50
Low Risk/BCG Casual Contacts Close Contacts TB patients
51
410
44
TST
QFT
Increase agreement with increased chance of infectionKang, 2005
:
60
70
80
90
100
Percentpositive
No BCG BCG
0
10
20
30
40
50
Casual contact Close contact Casual contact Close contact
TST
QFT
Good test agreement between TST & QFTBrock, 2004
QFTTSTQFT boosting
TST PPD Boosting
23
IGRA QFTG QFTG
IntubeQFTGIntube
TSPOT
ELISA ELISA ELISA ELISPOT ELISA ELISA ELISA ELISPOT
($) 29.22 26.74 25.09 57.79
Costs include facility space, equipment, consumables and staff timeTST$1214
-
2016/2/17
8
IGRAs
TSTIGRA TST+/IGRA :
IGRAs IGRAs
CCDRVol36June2010
6,530
InfectionControlandHospitalEpidemiology2010:31,12791285
IGRAs?
QFTTST25 TSTIGRA(TST/IGRA+)( / )
TSTIGRA(TST+/IGRA+)
IGRAs
IGRAsTSTTST
IGRAsTST
TSTIGRAs
CTSIGRAs IGRAs
IGRAsTSTs IGRAsTSTs
TST TSTIGRA TST/IGRA+ TSpot.TB
: IClin Microbiol Infect2011;17:806814
25233 IGRAs
(i)TSTIGRA TST (,) TST (,)
(ii)TSTIGRA, (iii)IGRATST (); (iv)IGRA,TST
IGRAs
-
2016/2/17
9
: IIClin Microbiol Infect2011;17:806814
IGRA
IGRAs IGRAs
TST(+)? ?
IGRA IGRAs
PCRDNA
+ +
+
-
2016/2/17
10
PCR
(>3) / /
81%
93%
100%
100%
ve P
osi
tivi
ty
0%
50%
First Second Third
Cu
mu
lati
v
-
2016/2/17
11
24
AFB(showninred)aretuberclebacilli
Number of bacilli seen Result reported
None per 100 oil immersion fields Negative
1-9 per 100 oil immersion fields Scanty, reportexact number
10-99 per 100 oil immersion fields 1+
1-10 per oil immersion field 2+
> 10 per oil immersion field 3+
60
70 HIVNegative
EarlyHIV
AFBpositivityinTBpatients
0
10
20
30
40
50
LateHIV
:
414
ColoniesofM.tuberculosis growingonmedia
:
MDRTB
-
2016/2/17
12
X 31,
2/3:
1014
:
/
:1.2.3.
NTM
NTMTST
- -
98%
Interobserveragreement
70%
AFB Microscopy X-ray
-
2016/2/17
13
98%
Specificity
50%
AFB Microscopy X-ray
Over-diagnosis
100%
Diagnosed by X-ray alone Actual cases
NTI, Ind J Tuberc, 1974
30%
1015%
40%
TomanK.Tuberculosiscasefindingandchemotherapy.WHO,1979
X
X
Arrowpointstocavityinpatient'srightupperlobe.
Early HIVLate HIV
(severe immuno-compromise)
420
1015
Rouillon A. Tubercle 1976;57:275-99
-
2016/2/17
14
70%
60
70
80
h la
b co
nfirm
atio
n
Expectedrange
27%
0
10
20
30
40
50
Non-DOTS DOTS
% o
f cas
es w
ith
1.
2.
3.
4.
5.
GuidanceofNationalTbProgrammes fortheManagementofTBinChildrenWHO/HTM/TB/2006.371
:
:
(..)
PCR
NAAT(NucleicAcidAmplificationTest)NAATPCR
FDANAAT 1995FDAMTD1995 FDAMTD
1999FDAMTD2
(OSPHL)GenProbeMTD2
NAAT
35 NTB
-
2016/2/17
15
NAAT
NAAT=95%,=98%
NAAT=66%,=98%
NAAT
+,NAAT+
+,NAAT
NAAT
,NAAT+
NAAT NAAT
,NAAT NAAT NAAT
NAAT
-
2016/2/17
16
NAAT
NAAT(:) NAATNAAT
